bob体育用户登录

<cite id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></cite>
<var id="p3bnh"><dl id="p3bnh"><address id="p3bnh"></address></dl></var>
<var id="p3bnh"></var>
<var id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></var>
<var id="p3bnh"></var>
<var id="p3bnh"></var>
<var id="p3bnh"><video id="p3bnh"><menuitem id="p3bnh"></menuitem></video></var>
<var id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></var>
<cite id="p3bnh"><video id="p3bnh"><menuitem id="p3bnh"></menuitem></video></cite>
<var id="p3bnh"><video id="p3bnh"></video></var><cite id="p3bnh"><span id="p3bnh"><thead id="p3bnh"></thead></span></cite>
<var id="p3bnh"><video id="p3bnh"></video></var>
<var id="p3bnh"><span id="p3bnh"></span></var>
<cite id="p3bnh"><span id="p3bnh"><menuitem id="p3bnh"></menuitem></span></cite>
<ins id="p3bnh"><span id="p3bnh"><menuitem id="p3bnh"></menuitem></span></ins>
<cite id="p3bnh"><video id="p3bnh"></video></cite>
<var id="p3bnh"><strike id="p3bnh"></strike></var>
<var id="p3bnh"></var>
<var id="p3bnh"></var>
<var id="p3bnh"></var><var id="p3bnh"><strike id="p3bnh"><listing id="p3bnh"></listing></strike></var>
<cite id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></cite>
Guangming Online> World

Therapeutic trial results against COVID-19 expected in 3 weeks: WHO chief

SWITZERLAND-GENEVA-WHO-NCP-THERAPEUTIC TRIAL RESULTS

The World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus (L) attends a daily briefing in Geneva, Switzerland, Feb. 20, 2020. WHO said Thursday that preliminary results from clinical trials of therapeutics against COVID-19 are expected in three weeks. (Xinhua/Chen Junxia)

GENEVA, Feb. 21 (Xinhua) -- The World Health Organization (WHO) said Thursday that preliminary results from clinical trials of therapeutics against COVID-19 are expected in three weeks.

"We're also looking forward to results from two clinical trials of therapeutics prioritized by the WHO R&D Blueprint," WHO Director-General Tedros Adhanom Ghebreyesus said at a daily briefing.

One of the trials he referred to is the combination of two drugs for HIV, lopinavir and ritonavir, while the other is testing an antiviral called remdesivir. "We expect preliminary results in three weeks," he added.

Remdesivir is a drug developed by U.S. pharmaceutical company Gilead Sciences. It has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments.

It has also shown fairly good antiviral activity against the COVID-19 at the cellular level. A randomized, double-blind, placebo-controlled clinical trial of remdesivir started on Feb. 6 in several hospitals in the central Chinese city of Wuhan, and the trial will last until the end of April.

A study published in 2004 showed the anti-HIV drug combination of Lopinavir and Ritonavir has "substantial clinical benefit" when given to patients who had SARS. The Wuhan Jinyintan Hospital, where the first 41 known patients were treated, has already launched a randomized, controlled trial of the anti-HIV drug combination, according to a report by Chinese researchers in the Lancet medical journal late last month.

The third version of COVID-19 treatment guidelines published by China's National Health Commission suggested that taking two Lopinavir/Ritonavir pills and inhaling a dose of nebulized alpha-interferon twice a day could benefit patients.

[ Editor: SRQ ]
<cite id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></cite>
<var id="p3bnh"><dl id="p3bnh"><address id="p3bnh"></address></dl></var>
<var id="p3bnh"></var>
<var id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></var>
<var id="p3bnh"></var>
<var id="p3bnh"></var>
<var id="p3bnh"><video id="p3bnh"><menuitem id="p3bnh"></menuitem></video></var>
<var id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></var>
<cite id="p3bnh"><video id="p3bnh"><menuitem id="p3bnh"></menuitem></video></cite>
<var id="p3bnh"><video id="p3bnh"></video></var><cite id="p3bnh"><span id="p3bnh"><thead id="p3bnh"></thead></span></cite>
<var id="p3bnh"><video id="p3bnh"></video></var>
<var id="p3bnh"><span id="p3bnh"></span></var>
<cite id="p3bnh"><span id="p3bnh"><menuitem id="p3bnh"></menuitem></span></cite>
<ins id="p3bnh"><span id="p3bnh"><menuitem id="p3bnh"></menuitem></span></ins>
<cite id="p3bnh"><video id="p3bnh"></video></cite>
<var id="p3bnh"><strike id="p3bnh"></strike></var>
<var id="p3bnh"></var>
<var id="p3bnh"></var>
<var id="p3bnh"></var><var id="p3bnh"><strike id="p3bnh"><listing id="p3bnh"></listing></strike></var>
<cite id="p3bnh"><video id="p3bnh"><thead id="p3bnh"></thead></video></cite>

网上welcome彩票平台手机登录

博冠的彩的网登录

m5体彩登录

千赢官方下载

彩客竞彩彩票官网apple

qy8千亿国际欢迎您

晓风彩票登陆

皇冠体育博彩皇冠

六福彩票注册平台

 

网上welcome彩票平台手机登录

博冠的彩的网登录

m5体彩登录

千赢官方下载

彩客竞彩彩票官网apple

qy8千亿国际欢迎您

晓风彩票登陆

皇冠体育博彩皇冠

六福彩票注册平台